Finance

Lists
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
$3.75
+0.81%
(+0.030) 1D
Sep 1, 3:34:53 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Open
$3.72
High
$3.80
Low
$3.67
Mkt. cap
411.11M
Avg. vol.
1.51M
Volume
726.06K
52-wk high
$5.45
52-wk low
$2.53
EPS
-$0.18
Beta
0.47
Shares outstanding
109.78M
No. of employees
202
Open
$3.72
High
$3.80
Low
$3.67
Mkt. cap
411.11M
Avg. vol.
1.51M
Volume
726.06K
52-wk high
$5.45
52-wk low
$2.53
EPS
-$0.18
Beta
0.47
Shares outstanding
109.78M
No. of employees
202
News stories
From web sources and news partners
About Rocket Pharmaceuticals Inc
CEO-
Employees202
Founded1999
HeadquartersCranbury, New Jersey, United States
SectorBiotechnology
Websiterocketpharma.com
Analyst ratings
Based on 9 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
6
Hold
3
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current $3.75
$15.00 (+300.00%)
Average
$11.14 (+197.07%)
Lowest
$5.00 (+33.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Keay Nakae
Chardan Capital
Buy
Maintained
$11.00
+193.3%
09/01/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$10.00
+166.7%
08/12/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$5.00
+33.3%
08/12/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$15.00
+300%
08/10/2026
Yun Zhong
Wedbush
Buy
Reiterated
$15.00
+300%
08/11/2026
Gil Blum
Needham
Hold
Reiterated
-
-
08/11/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/10/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$12.00
+220%
08/10/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$10.00
+166.7%
08/03/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$11.00
+193.3%
05/10/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
$11.00
+193.3%
03/27/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$3.00
-20%
03/27/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
$10.00
+166.7%
03/02/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
34.07M
29.35M
31.45M
29.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.35M
14.68M
17.06M
17.42M
Operating expense
52.42M
44.03M
48.51M
46.92M
Total operating expenses
52.42M
44.03M
48.51M
46.92M
Operating income
-52.42M
-44.03M
-48.51M
-46.92M
Other non operating income
-
-
-
-
EBT including unusual items
-50.33M
-42.54M
-47.59M
131.84M
EBT excluding unusual items
-52.18M
-43.81M
-48.82M
-47.05M
Income tax expense
-
-
-
8.62M
Effective tax rate
-
-
-
6.54%
Other operating expenses
-
-
-
-
Net income
-50.33M
-42.54M
-47.59M
123.21M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.38
-0.42
-0.38
Interest and investment income
709.00K
690.00K
161.00K
347.00K
Interest expense
-473.00K
-473.00K
-473.00K
-473.00K
Net interest expenses
236.00K
217.00K
-312.00K
-126.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.18M
-41.81M
-46.36M
-44.82M
Gain or loss from assets sale
-
-
-
-178.19M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps